Steven L. Hoerter

CIK: 0001533451

Transaction Breakdown

Open Market Buys (P)1 (6.7%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)14 (93.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (4)

MBX

MBX Biosciences, Inc.

DirectorOfficer

YARW

Yarrow Bioscience, Inc.

Director

CCCC

C4 Therapeutics, Inc.

Director

ORIC

Oric Pharmaceuticals, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (15 total)

MBX
MBX Biosciences, Inc.
Aug 3, 2026
Award(A)
Direct
71K shares-
CCCC
C4 Therapeutics, Inc.
Jun 24, 2026
Award(A)
Stock Option (Right to Buy)
Direct
62K shares-
MBX
MBX Biosciences, Inc.
Jun 4, 2026
Award(A)
Stock option (right to buy)
Direct
12.5K shares-
MBX
MBX Biosciences, Inc.
May 1, 2026
Award(A)
Direct
11.9K shares-
ORIC
Oric Pharmaceuticals, Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
40K shares-
MBX
MBX Biosciences, Inc.
Nov 22, 2025
Award(A)
Stock option (right to buy)
Direct
0 shares-
MBX
MBX Biosciences, Inc.
Nov 22, 2025
Award(A)
Stock option (right to buy)
Direct
8K shares-
MBX
MBX Biosciences, Inc.
Nov 6, 2025
Award(A)
Stock option (right to buy)
Direct
33.8K shares-
MBX
MBX Biosciences, Inc.
Nov 6, 2025
Award(A)
Stock option (right to buy)
Direct
100K shares-
MBX
MBX Biosciences, Inc.
Oct 17, 2025
Purchase(P)
Indirect
20K shares at avg. $13.25$265K
CCCC
C4 Therapeutics, Inc.
Jun 18, 2025
Award(A)
Stock Option (Right to Buy)
Direct
35.5K shares-
MBX
MBX Biosciences, Inc.
Jun 5, 2025
Award(A)
Stock option (right to buy)
Direct
16K shares-
MBX
MBX Biosciences, Inc.
Apr 7, 2025
Award(A)
Stock option (right to buy)
Direct
32K shares-
ORIC
Oric Pharmaceuticals, Inc.
Jan 2, 2025
Award(A)
Stock Option (right to buy)
Direct
35K shares-
CCCC
C4 Therapeutics, Inc.
Nov 19, 2024
Award(A)
Stock Option (Right to Buy)
Direct
65K shares-

		Type	Shares	Price		Ownership
Aug 3, 2026	MBX MBX Biosciences, Inc.	Award(A)	71,000	-	$0	Direct
Jun 24, 2026	CCCC C4 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	62,000	-	-	Direct
Jun 4, 2026	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	12,500	-	-	Direct
May 1, 2026	MBX MBX Biosciences, Inc.	Award(A)	11,938	-	$0	Direct
Jan 2, 2026	ORIC Oric Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	40,000	-	-	Direct
Nov 22, 2025	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	0	-	-	Direct
Nov 22, 2025	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	8,000	-	-	Direct
Nov 6, 2025	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	33,751	-	-	Direct
Nov 6, 2025	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	100,000	-	-	Direct
Oct 17, 2025	MBX MBX Biosciences, Inc.	Purchase(P)	20,000	$13.25	$264,984	Indirect
Jun 18, 2025	CCCC C4 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	35,500	-	-	Direct
Jun 5, 2025	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	16,000	-	-	Direct
Apr 7, 2025	MBX MBX Biosciences, Inc.	Award(A) Stock option (right to buy)	32,000	-	-	Direct
Jan 2, 2025	ORIC Oric Pharmaceuticals, Inc.	Award(A) Stock Option (right to buy)	35,000	-	-	Direct
Nov 19, 2024	CCCC C4 Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	65,000	-	-	Direct

1-15 of 15 transactions

About Hoerter Steven L.

Hoerter Steven L. (SEC CIK 0001533451) files insider reports with the SEC as President and CEO of MBX Biosciences, Inc. (MBX), Director of Yarrow Bioscience, Inc. (YARW) and Director of C4 Therapeutics, Inc. (CCCC). Signal8 also holds filings tied to 1 other company.

Signal8 holds 18 ownership filings by Hoerter Steven L. (3 Form 3, 15 Form 4), filed between Nov 21, 2024 and Aug 4, 2026. Those filings report 15 transactions, from Nov 19, 2024 to Aug 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hoerter Steven L.'s filings is in CARMEL, IN.

Recent filings by Hoerter Steven L.

Aug 3, 2026: Grant or award of MBX shares (Form 4, code A).
Jun 24, 2026: Grant or award of CCCC derivative securities (Form 4, code A).
Jun 4, 2026: Grant or award of MBX derivative securities (Form 4, code A).
May 1, 2026: Grant or award of MBX shares (Form 4, code A).
Jan 2, 2026: Grant or award of ORIC derivative securities (Form 4, code A).

Other insiders filing for MBX Biosciences, Inc. (MBX)

Radovich Peter, Director
Azoulay Salomon, Chief Medical Officer
Smither John W, Chief Financial Officer
Mathers Edward T, Director
Pescovitz Ora H., Director
Heron Patrick J, Director

How to read Form 4 transaction codes